Humanized Mice Model MarketSize, Share & Industry Analysis, 2026-2034By TypeBy ApplicationBy Humanization TechnologyBy Research ApplicationBy Product & Service Type

A humanized mouse or rat model is a laboratory animal engineered to carry components of the human immune system, such as human hematopoietic stem cells, peripheral blood mononuclear cells, or specific human genes inserted through genetic modification, so that its biological responses more closely mirror those of a human patient. These models are used to study how a human immune system interacts with a disease, a pathogen, or a candidate drug before that drug reaches human trials. Buyers include pharmaceutical and biotechnology companies developing oncology and immunology therapies, contract research organizations running preclinical studies on behalf of drug sponsors, and academic and government research institutions studying immune biology and infectious disease.

The global humanized mice model market is valued at USD 155 million in 2025 and is set to reach USD 298.5 million by 2034, a compound annual growth rate of 7.14% across the 2026-2034 forecast period. The study tracks the market across USD 88 million in 2020, USD 132 million in 2024, USD 172 million in 2026 and USD 231.5 million in 2030.

Composition changes more than the total does. Humanized Rat Models, at 11.93%, outgrows Humanized Mouse Models at 6.3%, and its share moves from 12% to 18%. Humanized Mouse Models stays the largest line throughout, at USD 136.4 million in 2025 and USD 244.8 million in 2034. Humanized Rat Models take share over the period; Humanized Mouse Models give it up while still growing in absolute terms.

By application, Pharmaceutical & Biotechnology Companies accounts for 52% of 2025 revenue at USD 80.6 million, reaching USD 143.3 million and 48% by 2034. Contract Research Organizations grows faster at 9.24% against 6.6%, moving from 33% of revenue to 38% by 2034. This axis divides the same revenue as the type split rather than adding to it, so the two are read together rather than summed.

The regional order runs from North America at 45% of 2025 revenue down to Middle East and Africa at 3.5%. North America is worth USD 69.7 million in 2025 and USD 119.4 million in 2034; Europe, second at 25%, moves from USD 38.8 million to USD 65.7 million. Share shifts toward Asia Pacific, Latin America and Middle East and Africa over the forecast period, which is what makes the regional split worth reading rather than assuming.

Behind these figures sit five regions, two type lines and five segmentation axes, each reported for every year from 2020 to 2034. The headline 2025 value is arrived at by triangulating published aggregates against category proxies, not by an independent count, and the same applies to the segment, regional and country breakdowns drawn from it.

• A forecast-period rate of 7.14% takes the market from USD 155 million in 2025 to USD 298.5 million in 2034, against 11.98% recorded over the 2020-2025 historical period.
• Humanized Mouse Models is the largest type line at USD 136.4 million in 2025, a 88% share, reaching USD 244.8 million and 82% of revenue by 2034.
• At 11.93%, Humanized Rat Models grows faster than any other type line, moving from USD 18.6 million and 12% of revenue in 2025 to USD 53.7 million and 18% in 2034.
• Scenario range for 2034 runs from USD 262.7 million in the bear case to USD 340.3 million in the bull case, against a base-case USD 298.5 million, the spread a plan built on this forecast has to absorb.
• The largest region is North America, generating USD 69.7 million in 2025 (45% of the global total) and USD 119.4 million by 2034, ahead of Europe at 25%.
• The United States accounts for 88% of North America in the base year, worth USD 61.3 million in 2025 and reaching USD 102.7 million by 2034, the worked country example carried through that region's chapters.
• The study covers 2020 through 2034 with 2025 as the base year, reporting five regions and five segmentation axes separately, with revenue, share and a growth rate for every line in each year.

Three things move over 2026-2034, and they are worth separating: the type mix, the regional balance, and the 7.14% compounding underneath both.

The direction of the market is not in question in any of the three. Each line and each region grows in revenue terms; the question is which takes the larger part of the growth.

Humanized Rat Models grows faster than Humanized Mouse Models. 11.93% against 6.3%: that gap, between Humanized Rat Models and Humanized Mouse Models, is the largest on the type axis. Humanized Rat Models takes its share of revenue from 12% to 18% while Humanized Mouse Models gives up ground, from 88% to 82%. The revenue figures behind that are USD 18.6 million to USD 53.7 million and USD 136.4 million to USD 244.8 million. Both expand; where a supplier sits on the axis still decides whether it tracks the market.

Growth concentrates in Asia Pacific, Latin America and Middle East and Africa. Asia Pacific moves from 22% of revenue in 2025 to 29% in 2034, worth USD 34.1 million rising to USD 86.6 million; Latin America moves from 4.5% of revenue in 2025 to 5% in 2034, worth USD 7 million rising to USD 14.9 million; Middle East and Africa moves from 3.5% of revenue in 2025 to 4% in 2034, worth USD 5.4 million rising to USD 11.9 million. Against that, North America at 45% moving to 40%, Europe at 25% moving to 22%, a fall in share, not in revenue. The practical consequence is that regional weighting decides whether a participant matches the market rate or trails it, regardless of how its own revenue reads.

Fifteen years without a discontinuity. Fifteen years of revenue run USD 88 million in 2020, USD 132 million in 2024, USD 155 million in 2025, USD 172 million in 2026, USD 231.5 million in 2030 and USD 298.5 million in 2034. The forecast rate of 7.14% sits against 11.98% over the historical period, so the projection extends an observed trend instead of proposing a new one. That moves the planning question away from timing a turn and onto the type and regional mixes, where the actual movement is.

Humanized Rat Models carries the market's growth rate

The 7.14% forecast rate rests on three things that can be measured separately: the size of the existing base, the mix shift on the type axis, and where regional growth is concentrated.

The bear case and what drives it

Where the forecast could be beaten

Revenue is concentrated in Humanized Mouse Models

In North America, 45% of global revenue puts 2025 at USD 69.7 million rising to USD 119.4 million in 2034. By revenue it sits first across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share stands at 40%, though revenue still rises throughout; what changes is the region's weight against faster-growing ones, which is not the same as weakening demand.

Segment composition follows the global pattern: Humanized Mouse Models largest at 88% of 2025 revenue, Humanized Rat Models fastest at 11.93%. North America is reported axis by axis and country by country in the full study.

USD 61.3 million of North America's 2025 revenue is generated in the United States, the region's largest market, reaching USD 102.7 million by 2034. At 88% of regional revenue in the base year it is not one market among several, the region's trajectory is largely this country's trajectory. Set against USD 69.7 million and USD 119.4 million for the region, it is why this market rather than a smaller one is the one reported in full.

Demand in the United States follows the type mix reported at global level: Humanized Mouse Models is the largest line at 88% of 2025 revenue, moving to 82% by 2034, while Humanized Rat Models grows fastest at 11.93% and takes its share from 12% to 18%. With 88% of North America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by type for the United States is reported separately in the full report.

In the United States, humanized mice used in biomedical research fall outside the Animal Welfare Act's coverage of purpose-bred mice, so oversight instead runs through the Public Health Service Policy on Humane Care and Use of Laboratory Animals, enforced at the institutional level by an Institutional Animal Care and Use Committee that must approve every protocol before animals are bred, engineered, or studied. Where genetic engineering or recombinant techniques are involved, work must also conform to the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules. Suppliers whose models feed into preclinical studies destined for an FDA submission must additionally produce data under Good Laboratory Practice standards, covering husbandry documentation, model characterization, and traceable colony records rather than a marketed-product label.

The suppliers tracked in this study (Ingenious Targeting Laboratory, Axen, Horizon Discovery Group PLC, HuMurine Technologies, Champions Oncology Inc., Trans Genic Inc., Crown Bioscience Inc., The Jackson Laboratory, Taconic Biosciences, Charles River Laboratories, Biocytogen, genOway and Cyagen Biosciences) compete in the United States across the type lines above. Two different problems sit on the same axis: holding Humanized Mouse Models at 88% of 2025 revenue, and taking Humanized Rat Models while it grows at 11.93%. Country-level positioning and shares for each of these companies are part of the full report rather than this summary.

5.4% of global revenue is generated in Canada; USD 8.4 million in 2025, reaching USD 16.7 million in 2034, and 12% of North America.

25% of the global humanized mice model market sits in Europe in 2025, worth USD 38.8 million with USD 65.7 million projected for 2034. That makes it the second-largest region covered, in 2025 and again in 2034.

Its share moves to 22% by 2034, and the region keeps growing in absolute terms while others expand faster, a change in relative weight, not a decline in demand.

Segment composition follows the global pattern: Humanized Mouse Models largest at 88% of 2025 revenue, Humanized Rat Models fastest at 11.93%. The full report breaks Europe out along every axis and by country.

The largest single market in Europe is Germany, at USD 12.4 million in 2025 and USD 20.4 million in 2034. 32% of the region in the base year makes it the largest market here without making it the region. Against regional totals of USD 38.8 million in 2025 and USD 65.7 million in 2034, it is the country the full report breaks out in detail.

The type pattern in Germany is the global one: 88% of 2025 revenue in Humanized Mouse Models, 82% by 2034, against 11.93% growth in Humanized Rat Models taking it from 12% to 18%. Since 32% of Europe's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-type revenue for Germany appears on its own in the full report.

In Germany, the production and use of humanized mice is governed by the Tierschutzgesetz, the national Animal Welfare Act implementing the EU Directive on the protection of animals used for scientific purposes, together with the Tierschutz-Versuchstierverordnung, which sets detailed husbandry, breeding, and procedure standards for laboratory rodents. Any protocol involving these animals requires prior authorization from the relevant state veterinary authority, following an ethics review that weighs scientific justification against animal welfare harm. Because humanized mice are genetically altered, their breeding and contained use also fall under the Gentechnikgesetz, Germany's genetic engineering law, which requires registered facilities, competence assessment of personnel, and biosafety containment appropriate to the risk class assigned to the modified strain.

In Germany the field is Ingenious Targeting Laboratory, Axen, Horizon Discovery Group PLC, HuMurine Technologies, Champions Oncology Inc., Trans Genic Inc., Crown Bioscience Inc., The Jackson Laboratory, Taconic Biosciences, Charles River Laboratories, Biocytogen, genOway and Cyagen Biosciences. Volume sits in Humanized Mouse Models at 88% of 2025 revenue; movement sits in Humanized Rat Models at 11.93% growth.

7% of global revenue is generated in the United Kingdom; USD 10.9 million in 2025, reaching USD 17.7 million in 2034, and 28.1% of Europe.

France is sized at USD 7 million in 2025, rising to USD 11.8 million by 2034; 4.5% of global revenue and 18% of Europe. It is reported separately from Germany across every segmentation axis in the full report.

USD 34.1 million of 2025 revenue is generated in Asia Pacific, 22% of the global humanized mice model market with USD 86.6 million projected for 2034. By revenue it sits third across the study, and the ranking does not change between 2025 and 2034.

By 2034 the share has moved up to 29%, so the region grows faster than the market's 7.14% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Segment composition follows the global pattern: Humanized Mouse Models largest at 88% of 2025 revenue, Humanized Rat Models fastest at 11.93%. Per-axis and per-country detail for Asia Pacific sits in the full report.

The largest single market in Asia Pacific is China, at USD 11.9 million in 2025 and USD 32.9 million in 2034. Its 34.9% of base-year regional revenue leads the region, though enough sits elsewhere that Asia Pacific is not a proxy for it. The region itself runs USD 34.1 million to USD 86.6 million over the same period, and this is the market carrying the country-level detail in the full report.

Demand in China follows the type mix reported at global level: Humanized Mouse Models is the largest line at 88% of 2025 revenue, moving to 82% by 2034, while Humanized Rat Models grows fastest at 11.93% and takes its share from 12% to 18%. Because the country carries 34.9% of Asia Pacific, a movement in its own mix shows up in the regional totals rather than being averaged away by neighbouring markets. China carries its own type breakdown in the full report.

In China, humanized mice fall under the Regulations on the Administration of Laboratory Animals administered by the Ministry of Science and Technology, which set licensing requirements for breeding facilities, quality standards for animal health and genetic background, and certification obligations that must accompany any strain supplied to a research user. Because these models are genetically modified and often involve human-derived cells or tissue, their import, export, and domestic transport are additionally subject to biosafety and quarantine approval from agricultural and customs authorities. Suppliers producing models intended to support drug evaluation submissions must further ensure their characterization data meets the expectations of the National Institutes for Food and Drug Control for nonclinical study quality.

The suppliers tracked in this study (Ingenious Targeting Laboratory, Axen, Horizon Discovery Group PLC, HuMurine Technologies, Champions Oncology Inc., Trans Genic Inc., Crown Bioscience Inc., The Jackson Laboratory, Taconic Biosciences, Charles River Laboratories, Biocytogen, genOway and Cyagen Biosciences) compete in China across the type lines above. Two different problems sit on the same axis: holding Humanized Mouse Models at 88% of 2025 revenue, and taking Humanized Rat Models while it grows at 11.93%.

Japan is sized at USD 9.2 million in 2025, rising to USD 19.1 million by 2034; 5.9% of global revenue and 27% of Asia Pacific. It is reported separately from China across every segmentation axis in the full report.

4.4% of global revenue is generated in India; USD 6.8 million in 2025, reaching USD 20.8 million in 2034, and 19.9% of Asia Pacific.

USD 7 million of 2025 revenue is generated in Latin America, 4.5% of the global humanized mice model market and reaches USD 14.9 million by 2034. That makes it the fourth-largest region covered, in 2025 and again in 2034.

By 2034 the share has moved up to 5%, on growth above the market's own 7.14%, and with a bigger contribution to the revenue added over the period than the base-year figure suggests.

Humanized Mouse Models leads here as it does globally, at 88% of 2025 revenue, and Humanized Rat Models again grows fastest at 11.93%. Per-axis and per-country detail for Latin America sits in the full report.

The largest single market in Latin America is Brazil, at USD 3.9 million in 2025 and USD 8 million in 2034. It accounts for 55.7% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 7 million to USD 14.9 million over the same period, and this is the market carrying the country-level detail in the full report.

Demand in Brazil follows the type mix reported at global level: Humanized Mouse Models is the largest line at 88% of 2025 revenue, moving to 82% by 2034, while Humanized Rat Models grows fastest at 11.93% and takes its share from 12% to 18%. With 55.7% of Latin America concentrated here, a change in this country's mix is visible in the regional figures instead of being diluted by its neighbours. Revenue by type for Brazil is reported separately in the full report.

In Brazil, the breeding and experimental use of humanized mice is regulated under the Arouca Law, which established the National Council for Control of Animal Experimentation, known as CONCEA, to license breeding and research facilities and to require ethics committee approval for every protocol involving live animals. Because humanized mice are genetically modified organisms, their development and handling also fall under the oversight of the National Technical Biosafety Commission, CTNBio, which classifies containment risk and authorizes contained use before any strain can be bred, imported, or distributed to a research customer. Suppliers must maintain facility registration and demonstrate compliance with both frameworks to legally supply these models within the country.

Competition in Brazil runs between the suppliers this study tracks: Ingenious Targeting Laboratory, Axen, Horizon Discovery Group PLC, HuMurine Technologies, Champions Oncology Inc., Trans Genic Inc., Crown Bioscience Inc., The Jackson Laboratory, Taconic Biosciences, Charles River Laboratories, Biocytogen, genOway and Cyagen Biosciences. Humanized Mouse Models, at 88% of 2025 revenue, is where the volume sits, and Humanized Rat Models, growing at 11.93%, is where position changes hands over the forecast period.

Within Latin America, Mexico accounts for 30% of regional revenue and 1.4% of the global total, worth USD 2.1 million in 2025 and USD 4.6 million by 2034.

USD 5.4 million of 2025 revenue is generated in Middle East and Africa, 3.5% of the global humanized mice model market rising to USD 11.9 million in 2034. That makes it the fifth-largest region covered, in 2025 and again in 2034.

Its share rises to 4% over the forecast period, so the region grows faster than the market's 7.14% and takes a larger part of the revenue added by 2034 than its 2025 weight implies.

Within the region the type split tracks the global one; 88% of 2025 revenue in Humanized Mouse Models, fastest growth of 11.93% in Humanized Rat Models. Revenue for Middle East and Africa is broken out by every segmentation axis and by country in the full report.

The largest single market in Middle East and Africa is Israel, at USD 2.2 million in 2025 and USD 4.5 million in 2034. It accounts for 40.7% of regional revenue in the base year, the largest single share without dominating the region outright. The region itself runs USD 5.4 million to USD 11.9 million over the same period, and this is the market carrying the country-level detail in the full report.

The type pattern in Israel is the global one: 88% of 2025 revenue in Humanized Mouse Models, 82% by 2034, against 11.93% growth in Humanized Rat Models taking it from 12% to 18%. Since 40.7% of Middle East and Africa's revenue is generated here, the regional numbers inherit this market's mix rather than smoothing it out. Per-type revenue for Israel appears on its own in the full report.

In Israel, humanized mice used in research are regulated under the Animal Welfare Law governing experiments on animals, which is overseen by the national committee responsible for animal experimentation, operating under the Ministry of Health, and which requires every research institution to maintain its own ethics committee empowered to approve, modify, or reject a proposed protocol before animals are bred or studied. Facilities producing or holding these genetically modified strains must hold institutional authorization and demonstrate husbandry and containment standards suited to a genetically altered rodent colony. Import of live humanized mice or their biological materials is additionally subject to veterinary and biosafety clearance from the relevant ministry authorities before entry is permitted.

Ingenious Targeting Laboratory, Axen, Horizon Discovery Group PLC, HuMurine Technologies, Champions Oncology Inc., Trans Genic Inc., Crown Bioscience Inc., The Jackson Laboratory, Taconic Biosciences, Charles River Laboratories, Biocytogen, genOway and Cyagen Biosciences are the suppliers covered in Israel. Humanized Mouse Models, at 88% of 2025 revenue, is where the volume sits, and Humanized Rat Models, growing at 11.93%, is where position changes hands over the forecast period.

Within Middle East and Africa, Saudi Arabia accounts for 25.9% of regional revenue and 0.9% of the global total, worth USD 1.4 million in 2025 and USD 3.2 million by 2034.

Request this sample to see the full data tables and segment-level detail behind this analysis.

This report assesses the market across every segment, with revenue and a growth rate for each line in each year of the study period. It covers the drivers, trends, opportunities, restraints and challenges shaping growth, the competitive landscape and the companies profiled, and the research methodology behind every estimate. Segmentation is reported by type, application, humanization technology, research application, product & service type, and regional analysis covers North America, Europe, Asia Pacific, Latin America, Middle East and Africa, each broken out by country.